Lookup NU author(s): Dr Lauren Walker,
Professor Johannes Attems
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
© 2019 International Society for Neurochemistry Lewy body diseases share clinical, pathological, genetic and biochemical signatures, and are regarded as a highly heterogeneous group of neurodegenerative disorders. Inclusive of Parkinson's disease (PD), Parkinson's disease dementia (PDD) and dementia with Lewy bodies (DLB), controversy still exists as to whether they should be considered as separate disease entities or as part of the same disease continuum. Here we discuss emerging knowledge relating to both clinical, and neuropathological differences and consider current biomarker strategies as we try to improve our diagnostic capabilities and design of disease modifying therapeutics for this group of debilitating neurodegenerative disorders. (Figure presented.).
Author(s): Walker L, Stefanis L, Attems J
Publication type: Review
Publication status: Published
Journal: Journal of Neurochemistry
Pages: epub ahead of print
Online publication date: 20/03/2019
Acceptance date: 14/03/2019
ISSN (print): 0022-3042
ISSN (electronic): 1471-4159
Publisher: Blackwell Publishing Ltd
PubMed id: 30892688